Instructor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Samantha M. Jaglowski, MD
|
|
Give Review
Samantha Jaglowski is an expert in the field of Oncology. She researched medicine at The Ohio State University College of Medicine. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Samantha M. Jaglowski is also published. She has 26 publications published. The lastest publication: "Ibrutinib for treatment of chronic lymphocytic leukemia.' Doctor Samantha M. Jaglowski, MD accepts all Medicare patients.
Publications
- Ibrutinib for treatment of chronic lymphocytic Leukemia.
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic Leukemia.
- Endothelial chimerism in Chronic sclerotic-type Chronic Graft-versus-Host disease and GVHD-associated angiomatosis.
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic Leukemia patients.
- Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
- Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic Leukemia.
- miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
- Lower dose of antithymocyte globulin does not increase Graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem ce...
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- Health-related quality of life in patients who develop bronchiolitis obliterans syndrome following allo-SCT.
- A phase 1/1b study of combined rituximab, bendamustine, and ibrutinib in patients with previously untreated and relapsed/refractory non-Hodgkin's Lymphoma.
- The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for Lymphoma and multiple myeloma.
- Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
- An effective mobilization strategy for Lymphoma patients after failed upfront mobilization with plerixafor.
- Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous Peripheral blood stem cell transplants in patie...
- Graft-versus-host disease: why have we not made more progress?
- Impact of targeted therapy on outcome of chronic lymphocytic Leukemia patients with relapsed del(17p13.1) karyotype at a single center.
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.
- Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for Chronic lymphocytic leukaemia.
- Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic Leukemia.
- The clinical application of monoclonal antibodies in chronic lymphocytic Leukemia.
- Lovenox hurts.
- Lymphoma in adolescents and young adults.
- Choosing first-line therapy for chronic lymphocytic Leukemia.
- Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic Leukemia and is effectively targeted by PCI-32765.
Schools
Ohio State University College Of Medicine and Public Health
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
The Ohio State University College of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1669674271 | |
| NPPES Provider LastName | JAGLOWSKI | |
| NPPES Provider FirstName | SAMANTHA | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology | |
| Total Claim Count | 51.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669674271 |
| Last Name Of The Provider | JAGLOWSKI |
| First Name Of The Provider | SAMANTHA |
| View All |
Similar Doctors
|
Dr. Charles L. Shapiro, MD |
|
|
Dr. Tanios S. Bekaii-Saab, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tarek A. Chidiac, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Arvinder S. Bhinder, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kari L. Kendra, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Manisha H. Shah, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Nseobong I. Ntukidem, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven K. Clinton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristen K. Ciombor, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven M. Devine, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jeanna L. Knoble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Woyach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Taral Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Drew R. Oostra, MD
This Doctor is OpenDoctor Recommended.
|